Biogen Idec Inc. disclosed six more cases of a rare brain infection in multiple sclerosis patients taking Tysabri, a medication it sells with Elan Corp. bringing the total number of cases to 85 as of Jan. 7.
The Weston, Mass., biotech company reported no new deaths among patients who have developed the infection--known as progressive multifocal leukoencephalopathy, or PML-- so the total stands at 16.
The number of PML cases is important because if the infection rate climbs too high, the drug's sales growth may drop. Regulators recently said that they watch the cases, but have concluded that the benefits of the medicine to MS patients outweigh the risks.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1905
